Fiera Capital Corp Purchases 1,398 Shares of Zoetis Inc. (NYSE:ZTS)

Fiera Capital Corp grew its stake in Zoetis Inc. (NYSE:ZTS) by 0.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 588,959 shares of the company’s stock after acquiring an additional 1,398 shares during the period. Fiera Capital Corp’s holdings in Zoetis were worth $115,071,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also made changes to their positions in the company. Sarasin & Partners LLP boosted its holdings in Zoetis by 546.3% during the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after buying an additional 1,904,899 shares during the last quarter. Swedbank AB bought a new position in shares of Zoetis during the 1st quarter worth approximately $210,815,000. International Assets Investment Management LLC grew its holdings in shares of Zoetis by 41,235.7% during the 3rd quarter. International Assets Investment Management LLC now owns 939,974 shares of the company’s stock worth $183,652,000 after purchasing an additional 937,700 shares in the last quarter. Marshall Wace LLP boosted its position in shares of Zoetis by 7,608.6% during the 2nd quarter. Marshall Wace LLP now owns 835,684 shares of the company’s stock worth $144,874,000 after acquiring an additional 824,843 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in Zoetis by 1.0% in the first quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after acquiring an additional 414,605 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

NYSE:ZTS traded up $1.55 during mid-day trading on Friday, reaching $175.80. The stock had a trading volume of 826,401 shares, compared to its average volume of 2,526,891. The stock has a market capitalization of $79.32 billion, a P/E ratio of 32.77, a P/E/G ratio of 2.61 and a beta of 0.90. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.09 and a current ratio of 3.69. Zoetis Inc. has a one year low of $144.80 and a one year high of $201.92. The firm has a 50 day moving average price of $188.46 and a two-hundred day moving average price of $179.17.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.46 by $0.12. The business had revenue of $2.40 billion for the quarter, compared to analyst estimates of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. Zoetis’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period last year, the company earned $1.36 EPS. As a group, analysts expect that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be paid a $0.432 dividend. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.98%. Zoetis’s payout ratio is presently 32.52%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Stifel Nicolaus raised their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. lifted their price target on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. BTIG Research lifted their price target on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Finally, Piper Sandler increased their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. Ten analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.